<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403376</url>
  </required_header>
  <id_info>
    <org_study_id>PDY11684</org_study_id>
    <secondary_id>2011-001160-21</secondary_id>
    <secondary_id>U1111-1115-2742</secondary_id>
    <nct_id>NCT01403376</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide</brief_title>
  <acronym>TERIVA</acronym>
  <official_title>Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide Treatment and Using a Population of Patients With Multiple Sclerosis as a Reference</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      Assess the antibody response to influenza vaccine in patients with relapsing form of multiple
      sclerosis (RMS) treated with teriflunomide compared to a reference population.

      Secondary Objectives:

        -  Assess the effect of teriflunomide on immunoglobulin levels;

        -  Assess the safety of influenza vaccination in patients with RMS treated with
           teriflunomide.

      The reference population was defined as multiple sclerosis (MS) patients with a stable
      treatment with interferon-β-1. Antibody response was measured using hemagglutination
      inhibition assay (HIA) and the hemagglutinin antigens representing the stains of H3N2, H1N1,
      and B as present in the influenza vaccine used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximum duration of the study period for a participant was approximatively 49 days broken
      down as follows:

        -  Screening period of up to 21 days;

        -  Influenza vaccination at Day 1;

        -  Follow-up period of 28 days (±2 days).

      MS treatment (Teriflunomide or interferon-β-1) was to be continued during the course of the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Antibody Titer ≥40 at 28 Days Post Vaccination</measure>
    <time_frame>28 days post vaccination</time_frame>
    <description>For each viral strain (H1N1, H3N2, and B), the antibody titer, level of antibodies in blood sample when exposed to antigen, was calculated as the mean of two replicates. If the titer was below or above the limit of detection, the threshold value was used.
The percentage of participants achieving a titer of 40 or more, as well as the 90% confidence interval (CI) using normal approximation were calculated for each strain and treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With 2 Fold or More Increase in Antibody Titer at 28 Days Post Vaccination</measure>
    <time_frame>pre vaccination (baseline) and 28 days post vaccination</time_frame>
    <description>Percentages of participants with an increase from baseline of 2-fold or more in antibody titers and 90% CIs using normal approximation were calculated for each strain and treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With 4 Fold or More Increase in Antibody Titer at 28 Days Post Vaccination</measure>
    <time_frame>pre vaccination (baseline) and 28 days post vaccination</time_frame>
    <description>Percentages of participants with an increase from baseline of 4-fold or more in antibody titers and 90% CIs using normal approximation were calculated for each strain and treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of Titers (GMT) Ratio Post/Pre Vaccination</measure>
    <time_frame>pre vaccination (baseline) and 28 days post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin Levels</measure>
    <time_frame>pre vaccination (baseline) and 28 days post vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Teriflunomide 7 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriflunomide 14 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN-β-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriflunomide</intervention_name>
    <description>Film-coated tablet
Oral administration</description>
    <arm_group_label>Teriflunomide 7 mg</arm_group_label>
    <arm_group_label>Teriflunomide 14 mg</arm_group_label>
    <other_name>HMR1726</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-β-1</intervention_name>
    <description>Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection</description>
    <arm_group_label>IFN-β-1</arm_group_label>
    <other_name>Rebif®</other_name>
    <other_name>Avonex®</other_name>
    <other_name>Betaseron®</other_name>
    <other_name>Betaferon®</other_name>
    <other_name>Extavia®</other_name>
    <other_name>Genfaxone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>Inactivated, split-virion influenza vaccine 2011-2012
One administration by intramuscular or intradermal route as per product specification</description>
    <arm_group_label>Teriflunomide 7 mg</arm_group_label>
    <arm_group_label>Teriflunomide 14 mg</arm_group_label>
    <arm_group_label>IFN-β-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Male or female patient &lt;60 years old with relapsing multiple sclerosis (RMS) either
        treated for at least 6 months with 7 or 14 mg teriflunomide in one of the studies LTS6048
        or LTS6050, or treated with a stable dose of interferon-β-1 for at least 6 months.

        Exclusion Criteria:

          -  Concomitant infectious pathology at the time of vaccination;

          -  MS relapse within 1 month before vaccination;

          -  Systemic corticosteroids within 1 month before the vaccination;

          -  Any contraindication to influenza vaccine;

          -  Any vaccination within the last 6 months;

          -  Prior use of any investigational drug or participation to a clinical trial within 1
             year (only for patients under interferon-β-1);

          -  Prior or concomitant use (for a minimum of 1 year before study entry) of cladribine,
             mitoxantrone, or other immunosuppressant agents such as azathioprine,
             cyclophosphamide, cyclosporin, methotrexate, mycophenolate, natalizumab (Tysabri®),
             leflunomide or fingolimod or other immunomodulator/immunosuppressant in development;

          -  Prior or concomitant use of glatiramer acetate within 1 year before study entry;

          -  Prior or concomitant use of intravenous immunoglobulins within 3 months before study
             entry;

          -  Pregnant or breast feeding women;

          -  Woman of childbearing potential without adequate contraception.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 040001</name>
      <address>
        <city>Wien</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124005</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124003</name>
      <address>
        <city>Greenfield Park</city>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124002</name>
      <address>
        <city>London</city>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124007</name>
      <address>
        <city>Montreal</city>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124008</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124001</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124009</name>
      <address>
        <city>Toronto</city>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276003</name>
      <address>
        <city>Berlin</city>
        <zip>10785</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276002</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643002</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804002</name>
      <address>
        <city>Ivano-Frankovsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804001</name>
      <address>
        <city>Kharkiv</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <results_reference>
    <citation>Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, Truffinet P, Benamor M, Chambers S, O'Connor PW. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013 Aug 6;81(6):552-8. doi: 10.1212/WNL.0b013e31829e6fbf. Epub 2013 Jul 12.</citation>
    <PMID>23851964</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <results_first_submitted>January 22, 2013</results_first_submitted>
  <results_first_submitted_qc>January 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2013</results_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment initiated in September 2011 was completed in December 2011. A total of 137 patients were screened at 14 sites in 5 countries.
Participants treated with teriflunomide were recruited in the LTS6048-NCT00228163 study and in the LTS6050-NCT00803049 study.</recruitment_details>
      <pre_assignment_details>In order to ensure at least 40 participants were enrolled in the teriflunomide 14 mg group while maintaining the blind in the study LTS6050 an interactive voice response system (IVRS) was set up to include participants from both studies LTS6048 and LTS6050 into this study.
128 participants were enrolled and vaccinated at 14 sites.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Teriflunomide 7 mg</title>
          <description>Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months</description>
        </group>
        <group group_id="P2">
          <title>Teriflunomide 14 mg</title>
          <description>Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months</description>
        </group>
        <group group_id="P3">
          <title>IFN-β-1</title>
          <description>Influenza vaccine in participants treated with a stable dose of interferon-β-1 (IFN-β-1) for at least 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Teriflunomide 7 mg</title>
          <description>Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months</description>
        </group>
        <group group_id="B2">
          <title>Teriflunomide 14 mg</title>
          <description>Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months</description>
        </group>
        <group group_id="B3">
          <title>IFN-β-1</title>
          <description>Influenza vaccine in participants treated with a stable dose of interferon-β-1 (IFN-β-1) for at least 6 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="46"/>
            <count group_id="B4" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.1" spread="7.9"/>
                    <measurement group_id="B2" value="43.8" spread="8.5"/>
                    <measurement group_id="B3" value="45.1" spread="10.8"/>
                    <measurement group_id="B4" value="45.0" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pre-vaccination antibody titer - H1N1 strain</title>
          <description>H1N1, H3N2 and B were the strains contained in the seasonal influenza vaccine used.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 10 and 40 (&lt;)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pre-vaccination antibody titer - H3N2 strain</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 10 and 40 (&lt;)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pre-vaccination antibody titer - B strain</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 10 and 40 (&lt;)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Antibody Titer ≥40 at 28 Days Post Vaccination</title>
        <description>For each viral strain (H1N1, H3N2, and B), the antibody titer, level of antibodies in blood sample when exposed to antigen, was calculated as the mean of two replicates. If the titer was below or above the limit of detection, the threshold value was used.
The percentage of participants achieving a titer of 40 or more, as well as the 90% confidence interval (CI) using normal approximation were calculated for each strain and treatment group.</description>
        <time_frame>28 days post vaccination</time_frame>
        <population>Per-protocol population: Enrolled and vaccinated participants with antibody assessments at Day 28, but excluding those with important events/deviations potentially impacting analysis (multiple sclerosis relapse, poor compliance to treatment, interfering concomitant drug). Participants were considered according to the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg</title>
            <description>Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg</title>
            <description>Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months</description>
          </group>
          <group group_id="O3">
            <title>IFN-β-1</title>
            <description>Influenza vaccine in participants treated with a stable dose of interferon-β-1 (IFN-β-1) for at least 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Antibody Titer ≥40 at 28 Days Post Vaccination</title>
          <description>For each viral strain (H1N1, H3N2, and B), the antibody titer, level of antibodies in blood sample when exposed to antigen, was calculated as the mean of two replicates. If the titer was below or above the limit of detection, the threshold value was used.
The percentage of participants achieving a titer of 40 or more, as well as the 90% confidence interval (CI) using normal approximation were calculated for each strain and treatment group.</description>
          <population>Per-protocol population: Enrolled and vaccinated participants with antibody assessments at Day 28, but excluding those with important events/deviations potentially impacting analysis (multiple sclerosis relapse, poor compliance to treatment, interfering concomitant drug). Participants were considered according to the treatment actually received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="93.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.4" lower_limit="93.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="97.7" lower_limit="93.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="82.2" upper_limit="97.8"/>
                    <measurement group_id="O2" value="76.9" lower_limit="65.8" upper_limit="88.0"/>
                    <measurement group_id="O3" value="90.7" lower_limit="83.4" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="93.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.4" lower_limit="93.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="93.0" lower_limit="86.6" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With 2 Fold or More Increase in Antibody Titer at 28 Days Post Vaccination</title>
        <description>Percentages of participants with an increase from baseline of 2-fold or more in antibody titers and 90% CIs using normal approximation were calculated for each strain and treatment group.</description>
        <time_frame>pre vaccination (baseline) and 28 days post vaccination</time_frame>
        <population>Per-protocol population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg</title>
            <description>Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg</title>
            <description>Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months</description>
          </group>
          <group group_id="O3">
            <title>IFN-β-1</title>
            <description>Influenza vaccine in participants treated with a stable dose of interferon-β-1 (IFN-β-1) for at least 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 2 Fold or More Increase in Antibody Titer at 28 Days Post Vaccination</title>
          <description>Percentages of participants with an increase from baseline of 2-fold or more in antibody titers and 90% CIs using normal approximation were calculated for each strain and treatment group.</description>
          <population>Per-protocol population as previously defined</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="22.6" upper_limit="47.4"/>
                    <measurement group_id="O2" value="30.8" lower_limit="18.6" upper_limit="42.9"/>
                    <measurement group_id="O3" value="46.5" lower_limit="34.0" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="22.6" upper_limit="47.4"/>
                    <measurement group_id="O2" value="41.0" lower_limit="28.1" upper_limit="54.0"/>
                    <measurement group_id="O3" value="51.2" lower_limit="38.6" upper_limit="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" lower_limit="34.5" upper_limit="60.5"/>
                    <measurement group_id="O2" value="51.3" lower_limit="38.1" upper_limit="64.4"/>
                    <measurement group_id="O3" value="58.1" lower_limit="45.8" upper_limit="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With 4 Fold or More Increase in Antibody Titer at 28 Days Post Vaccination</title>
        <description>Percentages of participants with an increase from baseline of 4-fold or more in antibody titers and 90% CIs using normal approximation were calculated for each strain and treatment group.</description>
        <time_frame>pre vaccination (baseline) and 28 days post vaccination</time_frame>
        <population>Per-protocol population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg</title>
            <description>Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg</title>
            <description>Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months</description>
          </group>
          <group group_id="O3">
            <title>IFN-β-1</title>
            <description>Influenza vaccine in participants treated with a stable dose of interferon-β-1 (IFN-β-1) for at least 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 4 Fold or More Increase in Antibody Titer at 28 Days Post Vaccination</title>
          <description>Percentages of participants with an increase from baseline of 4-fold or more in antibody titers and 90% CIs using normal approximation were calculated for each strain and treatment group.</description>
          <population>Per-protocol population as previously defined</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="11.6" upper_limit="33.4"/>
                    <measurement group_id="O2" value="20.5" lower_limit="9.9" upper_limit="31.1"/>
                    <measurement group_id="O3" value="39.5" lower_limit="27.3" upper_limit="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="13.7" upper_limit="36.3"/>
                    <measurement group_id="O2" value="23.1" lower_limit="12.0" upper_limit="34.2"/>
                    <measurement group_id="O3" value="41.9" lower_limit="29.5" upper_limit="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="24.9" upper_limit="50.1"/>
                    <measurement group_id="O2" value="30.8" lower_limit="18.6" upper_limit="42.9"/>
                    <measurement group_id="O3" value="51.2" lower_limit="38.6" upper_limit="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of Titers (GMT) Ratio Post/Pre Vaccination</title>
        <time_frame>pre vaccination (baseline) and 28 days post vaccination</time_frame>
        <population>Per-protocol population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg</title>
            <description>Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg</title>
            <description>Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months</description>
          </group>
          <group group_id="O3">
            <title>IFN-β-1</title>
            <description>Influenza vaccine in participants treated with a stable dose of interferon-β-1 (IFN-β-1) for at least 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Titers (GMT) Ratio Post/Pre Vaccination</title>
          <population>Per-protocol population as previously defined</population>
          <units>ratio post/pre vaccination</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="2.0" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.9" upper_limit="2.9"/>
                    <measurement group_id="O3" value="3.4" lower_limit="2.6" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.9" upper_limit="3.5"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.9" upper_limit="3.6"/>
                    <measurement group_id="O3" value="4.1" lower_limit="3.0" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="2.3" upper_limit="4.2"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.3" upper_limit="3.9"/>
                    <measurement group_id="O3" value="4.7" lower_limit="3.6" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunoglobulin Levels</title>
        <time_frame>pre vaccination (baseline) and 28 days post vaccination</time_frame>
        <population>Per-protocol population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg</title>
            <description>Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg</title>
            <description>Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months</description>
          </group>
          <group group_id="O3">
            <title>IFN-β-1</title>
            <description>Influenza vaccine in participants treated with a stable dose of interferon-β-1 (IFN-β-1) for at least 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Immunoglobulin Levels</title>
          <population>Per-protocol population as previously defined</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immunoglobulin M - pre vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.57"/>
                    <measurement group_id="O2" value="1.23" spread="0.59"/>
                    <measurement group_id="O3" value="1.14" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin M - 28-day post vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.56"/>
                    <measurement group_id="O2" value="1.27" spread="0.60"/>
                    <measurement group_id="O3" value="1.16" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin G - pre vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.35" spread="1.82"/>
                    <measurement group_id="O2" value="9.12" spread="2.24"/>
                    <measurement group_id="O3" value="12.03" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin G - 28-day post vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.57" spread="2.08"/>
                    <measurement group_id="O2" value="9.09" spread="2.25"/>
                    <measurement group_id="O3" value="12.25" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin A - pre vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.66"/>
                    <measurement group_id="O2" value="1.51" spread="0.64"/>
                    <measurement group_id="O3" value="2.27" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin A - 28-day post vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.68"/>
                    <measurement group_id="O2" value="1.50" spread="0.63"/>
                    <measurement group_id="O3" value="2.33" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE) were collected from signature of the Informed Consent Form (ICF) up to the last visit in the study.</time_frame>
      <desc>The analysis was performed on the included and vaccinated population and included all AE that developed or worsened from vaccination up to the end of study visit at Day 28.</desc>
      <group_list>
        <group group_id="E1">
          <title>Teriflunomide 7mg</title>
          <description>Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months</description>
        </group>
        <group group_id="E2">
          <title>Teriflunomide 14mg</title>
          <description>Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months</description>
        </group>
        <group group_id="E3">
          <title>IFN-β-1</title>
          <description>Influenza vaccine in participants treated with a stable dose of interferon-β-1 (IFN-β-1) for at least 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months after trial completion, the Investigator can present or publish results. The Investigator provides the Sponsor with a copy of the presentation or publication for review and comment at least 30 days in advance of its submission.
The Sponsor can delay the submission for a period not exceeding 90 days to allow for filing a patent application or such other measures as the Sponsor deems appropriate to establish and preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact_US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

